Edition:
United States

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

0.84USD
26 May 2017
Change (% chg)

$0.02 (+2.16%)
Prev Close
$0.82
Open
$0.81
Day's High
$0.86
Day's Low
$0.76
Volume
49,200
Avg. Vol
99,317
52-wk High
$8.77
52-wk Low
$0.76

Latest Key Developments (Source: Significant Developments)

Tandem Diabetes Care reports Q1 loss per share $0.75
Thursday, 27 Apr 2017 04:05pm EDT 

April 27 (Reuters) - Tandem Diabetes Care Inc -:Tandem Diabetes Care reports first quarter 2017 financial results.Q1 sales fell 5 percent to $19 million.Sees FY 2017 sales $100 million to $107 million.Tandem Diabetes Care Inc - company is reaffirming its annual financial guidance on a non-gaap basis.Qtrly loss per share $0.75.Q1 earnings per share view $-0.63, revenue view $15.7 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $-1.84, revenue view $102.7 million -- Thomson Reuters I/B/E/S.  Full Article

Tandem Diabetes reports public offering of 18 mln shares
Thursday, 23 Mar 2017 08:30am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes care announces pricing of underwritten public offering of common stock .Says public offering of 18.0 million common shares priced at $1.25 per share.  Full Article

Tandem Diabetes Care prices common stock offering of 18 mln shares
Thursday, 23 Mar 2017 06:47am EDT 

Tandem Diabetes Care Inc :Tandem Diabetes Care Inc - prices common stock offering of 18 million shares at $1.25 per share.  Full Article

Tandem Diabetes Care says offering 18 mln shares of common stock
Monday, 20 Mar 2017 09:48am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes Care Inc says offering 18 million shares of common stock, par value $0.001 per share - SEC filing Further company coverage: [TNDM.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Tandem Diabetes Care files for common stock offering of up to $57.5 mln
Wednesday, 8 Mar 2017 04:25pm EST 

Tandem Diabetes Care Inc :Tandem Diabetes Care files for common stock offering of up to $57.5 million - SEC filing.  Full Article

Tandem Diabetes Care qtrly loss per share $0.48
Wednesday, 8 Mar 2017 04:05pm EST 

Tandem Diabetes Care Inc : Tandem Diabetes Care reports 2016 financial results . Q4 sales fell 1 percent to $28.9 million . Sees FY 2017 non-GAAP sales $100 million to $107 million . Q4 revenue view $22.7 million -- Thomson Reuters I/B/E/S . Pump shipments grew 9 percent to 16,938 for year ended December 31, 2016 compared to 15,483 pumps shipped in 2015 . Non-GAAP sales decreased 15 percent to $24.8 million in Q4 of 2016 . Non-GAAP sales for Q1 2017 are estimated to be 15 percent of annual sales . Qtrly loss per share $0.48 . Q4 earnings per share view $-0.65, revenue view $22.7 million -- Thomson Reuters I/B/E/S .FY2017 revenue view $103.7 million -- Thomson Reuters I/B/E/S.  Full Article

Tandem Diabetes Care now taking orders for t:slim X2 Insulin Pump
Tuesday, 4 Oct 2016 08:30am EDT 

Tandem Diabetes Care Inc : Tandem Diabetes Care now taking orders for next-generation t:slim X2 Insulin Pump .Shipments of t:slim X2 Pump are expected to begin late October 2016.  Full Article

Tandem Diabetes Care Q2 sales $23 million
Thursday, 28 Jul 2016 04:05pm EDT 

Tandem Diabetes Care Inc : Non-Gaap operating margin is estimated to be in range of negative 52 percent to negative 62 percent for FY . As of June 30, 2016, company had $56.3 million in cash, cash equivalents and short-term investments . Tandem diabetes care reports second quarter 2016 financial results, updates 2016 guidance and announces new T:SLIM X2(TM) insulin pump and associated technology upgrade program . Q2 sales $23 million versus I/B/E/S view $23.1 million .Non-Gaap sales are now estimated to be in range of $105 million to $110 million for FY.  Full Article

Tandem Diabetes says announces expanded pediatric indication of t:slim insulin pump
Tuesday, 26 Jul 2016 08:15am EDT 

Tandem Diabetes Care Inc : Fda clearance of an expanded pediatric indication for t:slim insulin pump .Expanded pediatric indication of t:slim insulin pump for ages 6 and older.  Full Article

Tandem Diabetes Care, TypeZero Technologies announce license agreement
Thursday, 21 Jul 2016 08:15am EDT 

Tandem Diabetes Care Inc : Says financial details of agreement have not been disclosed . Terms of license agreement include a worldwide, non-exclusive license for use of Typezero's AP technology in future tandem products . Tandem Diabetes Care and Typezero Technologies announce license agreement to accelerate development and commercialization of closed-loop artificial pancreas system . Agreement also provides tandem access to Typezero's future AP innovations over next five years .Anticipate research version of tandem's T:SLIM insulin pump will be used alongside Typezero's AP Technology in IDCL trial.  Full Article

More From Around the Web